Therefore, WT1 protein is an attractive target for immunotherapy, and a WT1 peptide vaccine was used for active immunotherapy in CML in a phase I trial [16, 17]. The gene discussed is WT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.